| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5203131
Max Phase: Preclinical
Molecular Formula: C17H20F2N4OS
Molecular Weight: 366.44
Associated Items:
Representations
Canonical SMILES: C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2c1CNCC2
Standard InChI: InChI=1S/C17H20F2N4OS/c1-10(8-24)21-16-12-7-20-6-5-14(12)22-17(23-16)25-9-11-3-2-4-13(18)15(11)19/h2-4,10,20,24H,5-9H2,1H3,(H,21,22,23)/t10-/m1/s1
Standard InChI Key: BKSXVRDJSFJSQU-SNVBAGLBSA-N
Associated Targets(Human)
Interleukin-8 receptor B 3491 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 366.44 | Molecular Weight (Monoisotopic): 366.1326 | AlogP: 2.49 | #Rotatable Bonds: 6 |
| Polar Surface Area: 70.07 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 7.90 | CX LogP: 2.68 | CX LogD: 2.07 |
| Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.54 | Np Likeness Score: -1.48 |
References
| 1. Van Hoof M, Boon K, Van Loy T, Schols D, Dehaen W, De Jonghe S.. (2022) Identification of novel chemotypes as CXCR2 antagonists via a scaffold hopping approach from a thiazolo[4,5-d]pyrimidine., 235 [PMID:35313168] [10.1016/j.ejmech.2022.114268] |
Source
Source(1):